Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Steven Kong

Physician Assistant Brooklyn, NY Physician Assistant

NPI 1407142052 CMS profile 11062162

210 E 2Nd St, Brooklyn, NY 11218

Open in the dashboard

General payments

$65,879

809 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Kong of Brooklyn, NY is reported in the CMS Open Payments database as having received $65,879 across 809 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,580 143
2024 General $10,245 130
2023 General $7,214 136
2022 General $16,277 172
2021 General $21,564 228

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Kong
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Steven Kong were reported at $10,580. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Steven Kong Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $21,564 $132 $37–$438 $132
2022 $16,277 $155 $48–$522 $149
2023 $7,214 $167 $52–$557 $160
2024 $10,245 $178 $55–$600 $164
2025 $10,580 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $31,763 122 payments
  2. Biohaven Pharmaceuticals, Inc. $12,566 54 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $5,676 31 payments
  4. AbbVie, Inc. $2,696 57 payments
  5. AstraZeneca Pharmaceuticals LP $2,620 85 payments
  6. Esperion Therapeutics, Inc. $2,398 85 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,842 154 payments
  8. Amgen Inc. $1,065 43 payments
  9. Pfizer Inc. $826 36 payments
  10. Janssen Pharmaceuticals, Inc $604 16 payments
  11. Other $3,823 126 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43,745 46 payments
  2. Food and Beverage $20,679 757 payments
  3. Travel and Lodging $1,354 5 payments
  4. Gift $100 1 payment
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $18,242 85 payments
  2. Vemlidy $10,226 22 payments
  3. NEXLETOL $2,398 85 payments
  4. XIFAXAN $1,842 154 payments
  5. CREON $1,534 27 payments
  6. TRULANCE $1,391 113 payments
  7. FARXIGA $1,277 55 payments
  8. NEXLIZET $1,010 7 payments
  9. BREZTRI $982 21 payments
  10. NURTEC ODT Pain $698 30 payments
  11. Other $9,342 321 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 236 drugs

Part D claims

38,774

Median for Physician Assistant: 241

Drug cost

$5,809,305

Median for Physician Assistant: $4,110

Branded share of claims

35.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vascepa Icosapent Ethyl Brand 2,539 $921,323
Nexletol Bempedoic Acid Brand 1,306 $604,367
Farxiga Dapagliflozin Propanediol Brand 477 $275,440
Vemlidy Tenofovir Alafenamide Brand 195 $272,851
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 388 $245,793
Xarelto Rivaroxaban Brand 387 $226,849
Januvia Sitagliptin Phosphate Brand 381 $223,206
Evenity (2 Syringes) Romosozumab-Aqqg Brand 88 $207,593
Jardiance Empagliflozin Brand 327 $201,225
Prolia Denosumab Brand 115 $194,146

The 10 drugs with the highest cost, of 236 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Vemlidy
$3,258 195 —
FARXIGA
$375 477 —
XIFAXAN
$307 12 —
NURTEC ODT
$279 25 —
Livdelzi
$250 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

809 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record